122 related articles for article (PubMed ID: 4058012)
1. Doxorubicin pharmacokinetics in the rabbit.
Maniez-Devos DM; Baurain R; Trouet A; Lesne M
J Pharmacol; 1985; 16(2):159-69. PubMed ID: 4058012
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of daunorubicinol in the rabbit: comparison with daunorubicin.
Maniez-Devos DM; Baurain R; Trouet A; Lesne M
J Pharmacol; 1986; 17(1):14-20. PubMed ID: 3713197
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
Maniez-Devos DM; Baurain R; Lesne M; Trouet A
J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
[TBL] [Abstract][Full Text] [Related]
4. Effect of sublethal liver injury on doxorubicin metabolism.
August DA; Halter S; Brenner DE
Clin Cancer Res; 1995 Mar; 1(3):351-8. PubMed ID: 9815991
[TBL] [Abstract][Full Text] [Related]
5. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of fominoben-HCl in the dog and the rabbit (author's transl)].
Zimmer A
Arzneimittelforschung; 1979; 29(2):323-8. PubMed ID: 156029
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic properties of antileukemic and trypanocidal compounds with amidino and imidazolinyl groups.
Gluth WP; Busch U
Arzneimittelforschung; 1984; 34(11):1542-51. PubMed ID: 6543129
[TBL] [Abstract][Full Text] [Related]
10. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
Camaggi CM; Strocchi E; Martoni A; Angelelli B; Comparsi R; Pannuti F
Drugs Exp Clin Res; 1985; 11(4):285-94. PubMed ID: 3869807
[TBL] [Abstract][Full Text] [Related]
12. Effect of allyl alcohol-induced sublethal hepatic damage upon doxorubicin metabolism and toxicity in the rabbit.
Brenner DE; Anthony LB; Halter S; Harris NL; Collins JC; Hande KR
Cancer Res; 1987 Jun; 47(12):3259-65. PubMed ID: 3581067
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
15. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.
de Bruijn P; Verweij J; Loos WJ; Kolker HJ; Planting AS; Nooter K; Stoter G; Sparreboom A
Anal Biochem; 1999 Jan; 266(2):216-21. PubMed ID: 9888978
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.
Benjamin RS; Riggs CE; Bachur NR
Cancer Res; 1977 May; 37(5):1416-20. PubMed ID: 856462
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
[TBL] [Abstract][Full Text] [Related]
18. Toxicokinetics and biotransformation of 3-(4-methylbenzylidene)camphor in rats after oral administration.
Völkel W; Colnot T; Schauer UM; Broschard TH; Dekant W
Toxicol Appl Pharmacol; 2006 Oct; 216(2):331-8. PubMed ID: 16806338
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer.
Peterson C; Gunvén P; Theve NO
Cancer Treat Rep; 1986 Aug; 70(8):947-52. PubMed ID: 3460699
[TBL] [Abstract][Full Text] [Related]
20. The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit.
Taylor SM; Rodgers RM; Lynn RK; Gerber N
J Pharmacol Exp Ther; 1980 May; 213(2):289-99. PubMed ID: 7365688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
